

British
Chambers of
Commerce

**Trade
Accelerator**

Trade Accelerator: Singapore Life Sciences Cohort



British
Chambers of
Commerce

British
Chamber of Commerce
SINGAPORE

IN PARTNERSHIP WITH

SUPPORTED BY



Contents

Foreword	03
The BCC project team	04
Sequoia Genetics	05
GutSee Health	06
Vision Engineering	07
Axol Bioscience	08
Datar Cancer Genetics UK	09
Lant Medical	10
NunaBio	11
Particology	12
LightOx	13
EnsiliTech Ltd	14
Delivery Team UK	15



Foreword



Steve Lynch MBE
Director of
International Trade
British Chambers
of Commerce

The TradeAccelerator Programme has the potential to be truly transformative. The UK's businesses have never lacked ambition. They are innovative, globally minded and ready to grow. But our research shows many smaller firms are struggling to turn that aspiration into reality. Over the past few years, exporter confidence has softened as too many firms feel unsupported, and trade policy wins fail to translate into new deals on the ground. The opportunity is enormous, even a modest uplift in exports would inject billions of pounds into the UK economy. The challenge is not about strategy. The weak link has always been execution, and the Trade Accelerator is our answer.

This is a targeted, outcome-driven programme that is designed to convert Britain's global trade ambition into concrete export wins. Starting with life sciences in Singapore, we will equip high-potential UK businesses with the skills, networks and in-market backing to secure customers, partners and investment.

This is an entirely new way approach to building a trade pipeline. It will involve structured preparation, curated matchmaking, regulatory insight, a high-impact trade mission and sustained post-mission support to land deals. It is Team UK in action, with Chambers, government and finance, supported by NatWest, aligned behind one objective: helping British businesses win overseas. We expect tangible exports, new commercial partnerships and hundreds of new opportunities to be identified within the first year

I believe this programme marks a shift in how we approach trade, from aspiration to activation, from policy to performance. By backing our life sciences innovators to scale globally, we are not only supporting individual firms, but also strengthening the UK's position in one of the most competitive sectors in the world. This is about using practical economic diplomacy to boost British business, and the British Chambers of Commerce network is proud to be delivering it.

The British Chamber of Commerce and BritCham Singapore Team



Steve Lynch MBE
Director of
International Trade
British Chambers
of Commerce



Eve Halliday
Programme
Manager
British Chambers
of Commerce



Jayashree Sadanandan
Life Sciences
Consultant
British Chambers
of Commerce



David Kelly
Executive Director
BritCham Singapore



Lucy Haydon
Deputy Executive
Director
BritCham Singapore



Louise Beazor
Head of Trade
Services
BritCham Singapore



Sequoia Genetics Ltd

About

Sequoia Genetics delivers an integrated, genomics-driven analytics and consultancy service for pharmaceutical, biotechnology, and investment organisations.

Leveraging large-scale human genetics data, Mendelian randomisation, and AI-enabled analytical approaches, the company provides end-to-end support across target identification, validation, and clinical strategy development—enabling robust, data-driven decision-making in drug discovery and development.



Dr Dipender Gill

Chief Executive Officer and Founder

Sequoia Genetics Ltd

 +44 7904 843 810

 dipender.gill@sequoiagenetics.com

 <https://sequoiagenetics.com>

Translation and Innovation Hub
84 Wood Lane
London
W12 0BZ
United Kingdom



GutSee Health Ltd

About

GutSee has developed an advanced, AI enabled platform for rapid bacterial identification and precision bacteriophage therapy design. It integrates sequencing data from portable Oxford Nanopore MinION devices and standard sequencing platforms to enable automated identification of bacterial species, strains, and antimicrobial resistance (AMR) determinants.

At the core of the platform is a proprietary AI phage-bacteria matching engine based on a Multi Head Deep Bilinear Interaction Network, trained on millions of experimentally validated phage-host interaction records and hundreds of thousands of reference phage genomes. Using state of the art genomic language models, the system delivers high accuracy predictions to support targeted, safe phage selection and multi phage cocktail design.

The platform includes automated biosafety screening of all candidate phage genomes and supports rapid, scalable deployment via secure cloud infrastructure, with a field deployable edge version for low bandwidth or offline environments. It is bacteria and disease agnostic, enabling rapid redirection to new pathogens without retraining, and offering broader applications across healthcare, biosecurity, and infectious disease response.



Joanna Wiecek

CEO

GutSee Health Ltd

+44 7779 421 657

joanna@gutseehealth.com

<https://gutseehealth.com>

**GutSee Health Ltd
Campus Technology Hub
Daresbury Laboratory
Keckwick Lane
Daresbury, Warrington
WA4 4AD
United Kingdom**





Vision Engineering Ltd

About

Vision Engineering designs and manufactures advanced microscopes, inspection, and metrology systems for precision quality control. Its ergonomic, high-performance inspection solutions support manufacturers across a wide range of industries by improving accuracy, efficiency, and repeatability in inspection and measurement processes.



Ganesh Ramakrishnan

Director VESEA

Vision Engineering Ltd

+65 90845328

ganesh@visioneng.asia

<https://www.visioneng.com>

**The Freeman Building Galileo
Drive Send
Woking
Surrey
GU23 7ER
United Kingdom**



Axol Bioscience Ltd

About

Axol Bioscience is a leading provider of human induced pluripotent stem cell (iPSC) technologies, supplying high quality iPSC derived cells, reagents, and specialist services to support drug discovery and disease research.

The company enables researchers to generate more predictive, human relevant data across a range of therapeutic areas.



Dr Catherine Elton

Chief Business Officer

Axol Bioscience Ltd

+44 7304 034911

catherine.elton@axolbio.com

<https://axolbio.com>

Axol Bioscience Ltd
Roslin Innovation Centre
Charnock Bradley Building
Easter Bush Campus
Easter Bush
EH25 9RG
United Kingdom

DATAR CANCER GENETICS

Datar Cancer Genetics UK

About

Datar Cancer Genetics operates in the In Vitro Diagnostics (IVD) sector, delivering advanced, non-invasive diagnostic solutions that support early detection and precision medicine.

Its portfolio of **liquid biopsy-based cancer diagnostics** uses simple blood tests to enable **cancer screening, diagnosis, personalised treatment** selection, and ongoing disease monitoring.

By analysing circulating tumour cells (CTCs), circulating DNA, and other key biomarkers, the platform generates clinically actionable insights that support earlier detection and personalised oncology care.



Pankaj Porje
Associate Director

Datar Cancer Genetics UK

 +44 7405410348

 pankaj.porje@datarpgx.com

 <https://uk.datarpgx.com>

**10 Medawar Road
Surrey Research Park
Guildford
GU2 7AE
United Kingdom**



Lant Medical Ltd

About

More than 50% of the world's population are infected with H.pylori (4 billion people).

Helicobacter pylori (H. pylori) infections are treated with 2 or 3 antibiotics simultaneously, often leading to incomplete eradication. This current treatment is inadequate. It is a worldwide concern that antibiotics are gaining resistance.

Our first product to market HELIX treats the root cause and all the symptoms of H. pylori. It can be used as a monotherapy or in conjunction with existing therapies. HELIX aims to be an over-the-counter therapy, offering easier access to effective treatment, and clinically tested to become a prescriptive therapy.



Joanne Lant

CEO

Lant Medical Ltd

+44 7748 562 760

joanne@lantmedical.com

<https://lantmedical.com>

**Lant Medical Ltd
29 Argyle Street
Alnmouth
Northumberland
NE66 2SB
United Kingdom**



NunaBio Ltd

About

NunaBio is a biopharma development and manufacturing company specialising in synthetic biology-enabled DNA production. It has developed a fully integrated, cell free DNA synthesis platform that enables rapid, reliable manufacture of a wide range of DNA constructs, including complex sequences that are challenging for traditional suppliers. The platform supports applications across gene therapy, mRNA vaccines, CRISPR, and diagnostics.

NunaBio's technology enables DNA production to scale rapidly from milligram to kilogram quantities, reducing timelines from months to days. Production can be delivered through a centralised service model or via compact, low cost Microfoundries and larger Gigafoundries deployed directly within customer facilities. Automation, digital tools, and Digital Twin-enabled remote monitoring ensure consistent, high quality output across distributed sites.

By enabling up to 90% faster production timelines and cost reductions of 30-70% compared to microbial fermentation, NunaBio improves productivity and operational efficiency while delivering resilient, sovereign DNA supply chains through distributed, domestic manufacturing.



Dr Joe Hedley

CEO

NunaBio Ltd

+44 7930 115 705

joe.hedley@nunabio.com

<https://nunabio.com>

**NunaBio Ltd
The Biosphere
Draymans Way
Newcastle Helix
Newcastle upon Tyne
NE4 5BX
United Kingdom**



Particology Ltd

About

The company is a biotechnology services provider and contract research organisation (CRO) specialising in particle technology for pharmaceutical development. It supports pharmaceutical and biotechnology companies in the design and optimisation of particles that deliver the required stability, manufacturability, and performance for both active pharmaceutical ingredients (APIs) and finished drug products.

Through a combination of experimental expertise and tailored study design, the company offers services ranging from bespoke, single-material testing engagements to extensive screening and optimisation programmes. These larger studies are designed to generate the robust scientific understanding required to support scale-up, manufacturing readiness, and regulatory assessment.

Service packages are flexible and scalable, starting from targeted evaluations for specific materials through to comprehensive development programmes supporting complex formulation and production challenges.



John Murphy

Chief Operating Officer;

Particology Ltd

+44 01304 801622

john.murphy@particology.com

<https://www.particology.com>

Particology Ltd
Discovery Park House
Ramsgate Road
Sandwich
CT13 9ND
United Kingdom



LightOx Ltd

About

We are developing a portfolio of light activated cytotoxic therapeutics that have been formulated for use in the treatment of oral cancers via a topical delivery method. Our small molecule drugs act as selective therapeutics, where uptake and activity preferentially occurs in cancerous cells.

LightOx has developed a new class of small molecule fluorescent drug-like compounds which overcome the limitations of current light-based treatments. These compounds have intrinsic light activated cell killing properties and have the potential to revolutionise light-based therapeutic markets.



Dr Sam Whitehouse

CEO


LightOx Ltd

+44 7867 531 431

sam.whitehouse@lightox.co.uk

<https://lightox.co.uk>

LightOx Ltd
65 Westgate Rd
Newcastle upon Tyne
NE1 1SG
United Kingdom



EnsiliTech Ltd

About

It is estimated that more than 25% of vaccines worldwide are wasted, largely due to failures in vaccine cold chain transport and storage.

Ensilation® is a patent protected, novel method for encasing thermally unstable biomolecules within a silica network to prevent degradation at temperatures from -80 to +50°C, and improved shelf-life.

The technology is designed for both existing, and new biopharmaceutical formulations. It produces thermally stable products that do not rely on cold-chain logistics, preventing wastage, improving shelf-life and increasing the accessibility of biological therapeutics and diagnostics globally.

Unlike other stabilisation technologies, ensilation does not rely on lyophilisation or any harsh conditions. The technology is designed for both existing, and new biopharmaceutical formulations. It produces thermally stable products that do not rely on cold-chain logistics.



Dr Aswin Doekhie

Co-founder & Chief Technology Officer

Ensilicated Technologies Ltd

+44 7519 793033

aswin@ensilitech.com

<https://www.ensilitech.com>

EnsiliTech Ltd
Science Creates St Philips
Albert Road
Bristol
BS2 0XJ
United Kingdom

Delivered as Team UK

The Trade Accelerator is a coordinated national approach to UK export growth:



National coordination, insight, programme design



In market delivery, commercial support, matchmaking



SME capability building and financial readiness



Diplomatic alignment and UK government backing



Bringing specialist expertise as the programme evolves

Together, we create one unified route for ambitious UK SMEs to grow internationally with confidence.

Ready to Unlock International Growth?

International expansion doesn't have to feel complex or high risk.

With the British Chambers of Commerce Trade Accelerator, you gain the clarity, capability, and trusted in market partners needed to succeed.

British Chambers of Commerce

Connecting UK ambition with global opportunity.